Jeffrey Teckman, MD, a professor of pediatrics at Saint Louis University, will serve as the principal investigator of a study examining the safety and efficacy of new hepatitis C drug treatments in children.
The multi-center clinical study will investigate the combination of Sofosbuvir and Ribavirin in children between ages 3 and 17. The combined drug therapy has shown 90 percent to 100 percent cure rate in adult patients, according to the report. Dr. Teckman hopes to discover similar results in pediatric patients.
"A lot of times studies for children don't get approved. The exciting part with our study is that the medication has already been tested in adults, and we are moving rapidly to test in children," said Dr. Teckman.
More articles on gastroenterology:
Drug therapy for celiac disease?
FDA grants tentative approval of UCERIS for ulcerative colitis
Antidepressants may increase GI bleeding risk
The multi-center clinical study will investigate the combination of Sofosbuvir and Ribavirin in children between ages 3 and 17. The combined drug therapy has shown 90 percent to 100 percent cure rate in adult patients, according to the report. Dr. Teckman hopes to discover similar results in pediatric patients.
"A lot of times studies for children don't get approved. The exciting part with our study is that the medication has already been tested in adults, and we are moving rapidly to test in children," said Dr. Teckman.
More articles on gastroenterology:
Drug therapy for celiac disease?
FDA grants tentative approval of UCERIS for ulcerative colitis
Antidepressants may increase GI bleeding risk